Literature DB >> 17707353

Glycine stimulates the release of labeled acetylcholine but not dopamine nor glutamate from superfused rat striatal tissue.

Marina Sorrentino Hernandes1, Leandro de Magalhães, Lanfranco Ranieri Paolo Troncone.   

Abstract

Glycine is known as an inhibitory neurotransmitter in the spinal cord and forebrain but its precise role in the forebrain is largely overlooked. This investigation evaluated whether glycine alters acetylcholine, glutamate or dopamine release from striatal tissue using an in vitro approach. We observed that while glycine induced a robust (3)H-acetylcholine release ((3)H-ACh) from superfused striatal tissue, it failed at releasing (3)H-glutamate or (3)H-dopamine. Glycine stimulated (3)H-ACh release in a dose- and calcium-dependent manner (EC(50)=69 microM). Tetrodotoxin (1 microM) inhibited about 75% of the release demonstrating a predominant dendritic and cell body location of glycine receptors. The prototypical glycine receptor antagonist strychnine at 10 microM completely abolished (3)H-ACh release. To further characterize the role of striatal glycine receptors in (3)H-ACh release we examined glycine effects after in vivo treatment with Haloperidol-decanoate (HD). Treatment for 30 days or more with HD decreased maximal glycine-stimulated release of (3)H-ACh suggesting a non-competitive inhibition. After 30 days of washout release parameters did not return to vehicle-treated levels. The glutamate agonist NMDA also stimulated acetylcholine release but showed slightly different behavior in HD-treated striatal tissue. These effects could be attributed to changes in chloride transporters expressed in the giant striatal cholinergic cell as well as glycine receptor subunit composition and finally, GABA/glycine co-release in this tissue.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17707353     DOI: 10.1016/j.brainres.2007.06.090

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  6 in total

1.  Dissociating scopolamine-induced disrupted and persistent latent inhibition: stage-dependent effects of glycine and physostigmine.

Authors:  Segev Barak; Ina Weiner
Journal:  Psychopharmacology (Berl)       Date:  2010-02-24       Impact factor: 4.530

Review 2.  Glycine as a neurotransmitter in the forebrain: a short review.

Authors:  Marina Sorrentino Hernandes; Lanfranco R P Troncone
Journal:  J Neural Transm (Vienna)       Date:  2009-10-14       Impact factor: 3.575

3.  Subregion-Specific Modulation of Excitatory Input and Dopaminergic Output in the Striatum by Tonically Activated Glycine and GABA(A) Receptors.

Authors:  Louise Adermark; Rhona B C Clarke; Mia Ericson; Bo Söderpalm
Journal:  Front Syst Neurosci       Date:  2011-10-18

4.  Protective Effects of a synthetic glycosaminoglycan mimetic (OTR4132) in a rat immunotoxic lesion model of septohippocampal cholinergic degeneration.

Authors:  Patricia Marques Pereira; Dulce Papy-Garcia; Denis Barritault; Franck Chiappini; Rolf Jackisch; Sarah Schimchowitsch; Jean-Christophe Cassel
Journal:  Glycoconj J       Date:  2022-03-07       Impact factor: 2.916

5.  Extrasynaptic glycine receptors of rodent dorsal raphe serotonergic neurons: a sensitive target for ethanol.

Authors:  Edward P Maguire; Elizabeth A Mitchell; Scott J Greig; Nicole Corteen; David J K Balfour; Jerome D Swinny; Jeremy J Lambert; Delia Belelli
Journal:  Neuropsychopharmacology       Date:  2013-11-22       Impact factor: 7.853

6.  Comprehensive urinary metabolomic profiling and identification of potential noninvasive marker for idiopathic Parkinson's disease.

Authors:  Hemi Luan; Liang-Feng Liu; Zhi Tang; Manwen Zhang; Ka-Kit Chua; Ju-Xian Song; Vincent C T Mok; Min Li; Zongwei Cai
Journal:  Sci Rep       Date:  2015-09-14       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.